TIDMAPOL 
 
30 June 2022 
 
                            Apollon Formularies Plc 
 
                         ("Apollon" or the "Company") 
 
                              Total Voting Rights 
 
In accordance with the Financial Conduct Authority's Disclosure and 
Transparency Rules, the Company hereby announces that it has 752,725,356 
ordinary shares of no par value each in issue, each share carrying the right to 
one vote. 
 
This figure of 752,725,356 ordinary shares may be used by shareholders in the 
Company as the denominator for the calculations by which they will determine if 
they are required to notify their interest in, or a change in their interest 
in, the share capital of the Company under the FCA's Disclosure and 
Transparency Rules. 
 
The directors of the Company accept responsibility for the contents of this 
announcement. 
 
                                    -ENDS- 
 
For further information please contact: 
 
Apollon Formularies 
 
Tel:    +44 771 198 0221 
 
Stene Jacobs    stene@apollon.org.uk 
 
Peterhouse Capital Limited (Corporate Adviser) 
 
Tel:    +44 207 220 9795 
 
Guy Miller      gm@peterhousecapital.com 
 
BlytheRay (Financial PR/IR-London) 
 
Tel:    +44 207 138 3204 
 
Tim Blythe/Megan Ray    apollon@blytheray.com 
 
About Apollon and Apollon Jamaica 
 
Apollon Formularies plc is an international medical cannabis company 
headquartered in the United Kingdom. Apollon Formularies Jamaica Limited is a 
pharmaceutical company incorporated and operating in the Commonwealth of 
Jamaica. Apollon Jamaica is licensed by the Jamaican government's Cannabis 
Licensing Authority (CLA) to cultivate, perform research and development, 
process, and sell medical cannabis therapeutic products that include legal 
medical cannabis to treat various illnesses under medical supervision. Apollon 
and Apollon Jamaica are parties to a Commitment Agreement whereby Apollon is 
entitled to 95% of Apollon Jamaica's Net Profits, and per a Stock Pledge 
Agreement that includes Stephen D. Barnhill, M.D., Apollon is to be assigned 
the entire 49% equity interest of Apollon Jamaica held by Dr. Barnhill, which 
is the maximum interest in a medical cannabis company allowed to be held by a 
non-Jamaican, upon the CLA approving the assignment. 
 
 
 
END

(END) Dow Jones Newswires

June 30, 2022 07:33 ET (11:33 GMT)

Apollon Formularies (AQSE:APOL)
Historical Stock Chart
From Feb 2023 to Mar 2023 Click Here for more Apollon Formularies Charts.
Apollon Formularies (AQSE:APOL)
Historical Stock Chart
From Mar 2022 to Mar 2023 Click Here for more Apollon Formularies Charts.